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Abstract: The objective of this study was to assess the effectiveness and safety of levosulpiride
in patients with dysmotility-like functional dyspepsia including nonerosive reflux esophagitis
in conditions of daily practice. The study was conducted as a prospective, open-label,
multicenter design in 342 patients with dysmotility-like functional dyspepsia (n=279) and
nonerosive reflux disease (n=63), who received levosulpiride 25 mg 3 times daily orally for 4
weeks. Individual symptoms (pain/discomfort, fullness, bloating, early satiety, pyrosis,
regurgitation, and nausea/vomiting) and a global symptom score were assessed at 15, 30, and
60 days after starting treatment. Adverse events also were recorded. There were 151 men and
191 women (mean age 38.8 years) who referred dyspeptic symptoms for a mean of 10.2
(10.7) months. A total of 66.4% patients were treated with 75 mg/day levosulpiride and 33.6%
with 50 mg/day. At the 15-day visit, a decrease greater than 50% in the global symptom score
was observed. The frequency and intensity of individual symptoms showed a statistically
significant decrease (p<0.001) at all visits compared with baseline. At the 30-day visit, all
symptoms had almost disappeared, a trend that was maintained until the last visit. Treatment
with levosulpiride was well tolerated and only 40 adverse events were recorded (galactorrhea
26.7%, somnolence 17.8%, fatigue 11.1%, headache 11.5%) and no patient had to abandon
the study due to side effects. In conclusion, levosulpiride is an effective and safe drug in the
treatment of dysmotility-like functional dyspepsia and non-erosive reflux disease.
Keywords: (MeSH terms): sulpiride/administration & dosage, dyspepsia/drug therapy,
levosulpiride, sulpiride/analogs & derivatives, administration oral, adult
Introduction
A common challenge in primary care is how best to evaluate and treat patients with
dyspepsia. Dyspepsia accounts for a relevant workload for general practitioners
(Heikkinen et al 1996; Van Bommel et al 2001; Maconi et al 2002). Results of different
studies have shown that the proportion of patients with dyspepsia who consulted
their general practitioner varied widely from 3% to 45% (Jones and Lydeard 1989;
Bodger et al 2000) among the eight doctors who participated in a prevalence study
of dyspepsia (Jones and Lydeard 1989). In population-based surveys carried out in
England, an overall six month prevalence of dyspepsia of 38% has been reported
(Jones and Lydeard 1992). In a study carried out in Denmark, the annual incidence
rate of dyspepsia was 3.4% (Meineche-Schmidt and Krag 1998), but in a random
Mediterranean population, the prevalence of dyspepsia was 24% (Caballero Plasencia
et al 2000).
Dyspepsia has been recently considered as a biopsychosocial disorder with
dysregulation of the brain–gut axis being central in origin of disease (Chua 2006).
The pathophysiology of functional dyspepsia is unknown, but a number of
mechanisms have been suggested. There is considerable evidence to suggest an
association between disordered motility and symptom production in functional
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dyspepsia. Motor dysfunction includes antral hypomotility
and delayed gastric emptying, myoelectrical abnormalities
of the gastric rhythm, abnormal tone (impaired gastric
accommodation), or maldistribution of food within the
stomach (Stanghellini et al 2004). Although abnormal
gastrointestinal motility may be the cause of the symptom
production, the focus of research is shifting more toward
sensory dysfunction as a primary abnormality, particularly
selective visceral hypersensitivity to mechanical distension,
acid hypersensitivity, or abnormal central processing of
nociceptive stimuli (Timmons et al 2004). The role of
Helicobacter pylori in symptom production in the absence
of mucosal lesions is controversial, although H. pylori
eradication is recommended in patients in whom no other
causes of symptoms has been identified (Malfertheiner et
al 2002). According to motor and/or sensory functional
abnormalities causing dyspeptic symptoms, treatment
options with prokinetics, serotoninergic agents, antacids,
and pain modulating medications have been proposed,
although proton-pump inhibitor drugs (PPIs), histamine-2
receptor antagonists, and prokinetic agents are the most
commonly used (Malagelada 2001; Talley 2003a; Bytzer
2004; Delgado-Aros et al 2004).
Antidopaminergic gastrointestinal prokinetics
(bromopride, clebopride, domperidone, levosulpiride, and
metoclopramide) have been exploited clinically for the
management of motor disorders of the upper gastrointestinal
tract (Andresen and Camilleri 2006). The prokinetic effect
of these drugs is mediated through the blockade of enteric
(neuronal and muscular) inhibitory D2 receptors. In this
respect, levosulpiride, a selective dopamine D2-receptor
antagonist with prokinetic activity, is a therapeutic option
in the management of functional dyspepsia on the basis of
dopaminergic pathways controlling gastrointestinal motility
(Distrutti et al 2002). On the other hand the serotonergic
(5-HT4) component of levosulpiride may enhance its
therapeutic efficacy in functional dyspepsia (Tonini et al
2004). Different studies, many of them carried out in Italy
(Macarri et al 1991; Gatto et al 1992; Arienti et al 1994;
Corazza et al 1996) where levosulpiride has been in the
market for more than 15 years, have demonstrated the high
efficacy of the drug in the control of dyspeptic symptoms
and its favorable safety profile. In a review conducted to
assess the clinical pharmacology, therapeutic efficacy and
tolerability of levosulpiride (Corazza and Tonini 2000), the
incidence of adverse events was 11% in 840 patients with
dyspepsia; most of them were mild and they resulted in
treatment discontinuation in only eight cases (0.9%). The
efficacy of levosulpiride and cisapride in reducing gastric
emptying times with no relevant side-effects was found to
be similar (Mansi et al 2000), and in a randomized, double-
masked trial, levosulpiride was at least as effective as
cisapride in the treatment of dysmotility-like functional
dyspepsia (Mearin et al 2004).
This study was conducted to assess the effectiveness and
safety of levosulpiride in patients with dysmotility-like
functional dyspepsia, including nonerosive reflux disease
in conditions of daily practice.
Patients and methods
This was a prospective, open-label, observational,
multinational study conducted between June 1, 2004 and
November 9, 2004, at 9 sites in Latin American (Costa Rica,
El Salvador, Guatemala, Honduras, Nicaragua, Panama,
Paraguay, Peru, and Dominican Republic) and was globally
coordinated (1 site) in Spain. The study was carried out in
the primary care setting. The objective of the study was to
assess the effectiveness and tolerability of levosulpiride in
the treatment of patients with functional dyspepsia.
Levosulpiride was administered during 4 weeks according
to the conditions of use established in the product’s technical
form in any of the two available presentations (tablets or
oral solution formulation). The duration of the study was 8
weeks (4-week treatment period and 4-week follow-up
period). All patients were fully informed on the purposes
and characteristics of the study and gave oral consent.
Approval of the study protocol by the local ethics
committees of the participating centers was not obtained
because the study medication was a commercialized product
and was prescribed for approved indications of use.
Patients aged 18 to 70 years of age with at least three of
the following symptoms: postprandial upper abdominal
fullness, postprandial pain/discomfort centered in the upper
abdomen, postprandial heaviness, early satiety, nausea,
pyrosis, and regurgitation were included in the study
provided that symptoms had been presented at least twice a
week within the preceding 3 weeks. To be included in the
study, patients were required to have available the results
of routine laboratory tests (blood cell count, biochemical
profile, and urinalysis) and an upper gastrointestinal
endoscopy carried out within the preceding 12 months.
Patients with history or suspicion of organic lesion were
excluded from the study as were patients undergoing
abdominal surgery, patients with lactose intolerance,
pregnant women or nursing mothers, and patients treatedTherapeutics and Clinical Risk Management 2007:3(1) 151
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with drugs or medications that were known to affect
gastrointestinal motility.
The study included 4 visits and its duration was of 60
days. At the baseline visit, the physician checked the
eligibility criteria, and treatment with levosulpiride (Dislep
®,
Ferrer Grupo, Barcelona, Spain) 25 mg three times (TID)
daily was begun.
Individual symptoms (postprandial pain/discomfort,
postprandial fullness, postprandial bloating or abdominal
distention, early satiety, nausea, vomiting, pyrosis, and
regurgitation) were assessed at baseline and at 15, 30, and
60 days (visits 1, 2, and 3, respectively) after starting
treatment. A computer-based questionnaire was used to
assess the frequency and severity of symptoms. The
frequency of symptoms was assessed according to a 4-point
scale (0 = no symptom, 1 = symptom present for 1–2 days
per week, 2 = 3–4 days a week, 3 = 5 or more days a week,
4 = symptoms present every day), with a total score from 0
to 10. The severity of symptoms was scored as 0 = no
symptom, 1 = mild and easily tolerable, 2 = moderate or
affecting normal daily activities, and 3 = severe or
preventing normal daily activities, with a total score from 0
to 6. A global symptom score that included upper abdominal
pain, postprandial upper pain or discomfort, postprandial
heaviness, early satiety, nausea, pyrosis, and regurgitation
was also calculated.
Adverse events were monitored throughout the study.
All adverse events reported by the patients or observed by
the investigators were recorded, and rated by the investigator
as to their relationship to the study drug (not related, possibly
related, probably or definitely related) and by their severity
(mild, moderate, or severe). Compliance with the prescribed
dosing regimen and concomitant medication was assessed
at the follow-up visits. At the final visit, patients and
physicians rated the overall efficacy of treatment in a
qualitative scale as excellent, good, regular, or bad.
The intent-to-treat (ITT) data set included all patients
who were assessed at baseline and attended at least one
follow-up visit (at 15, 30, and/or 60 days). The safety
population included all patients who were assessed at
baseline and received at least one dose of the study
medication. Data are expressed as mean and standard
deviation (SD) for quantitative variables or numbers and
percentages for categorical variables. The Wilcoxon signed-
rank test and the Cochran Q test were used for the analysis
of data. The independent effect of confounding variables
(age, sex), diagnostic group, and variables statistically
significant in the bivariate analysis were included in a
logistic regression model, with response to treatment with
levosulpiride, defined as a reduction of at least 5 points in
the symptom score at the final visit compared with baseline,
as the dependent variable. The SPSS 10.0 for Windows
(SPSS Inc., Chicago, IL) was used for all statistical
calculations. Statistical significance was defined as p<0.05.
Results
During the study period, treatment with levosulpiride was
indicated in a total of 346 patients. Four patients, however,
were excluded because inclusion criteria were not met.
Therefore, 342 patients, 151 men and 191 women, with a
mean (SD) age of 38.8 (12.3) years were included in the
study and were treated with the study medication. There
were 279 (81.6%) patients with dysmotility-like functional
dyspepsia and 63 (18.4%) with nonerosive reflux disease.
A total of 66.4% patients were treated with 75 mg/day of
levosulpiride and 33.6% with 50 mg/day. Twenty-two
patients were lost at follow-up, so that the evaluated number
of patients was 341 at visit 1, 331 at visit 2, and 321 at visit
3.
Baseline characteristics of the study population are
summarized in Table 1. Overall, patients had suffered
dyspeptic symptoms for a mean of 10.2 (10.7) months before
entering the study. Duration of symptom was less than 6
months in 148 patients, between 6 and 12 months in 76
patients, and more than 12 months in the remaining 118.
Patients in whom dyspeptic symptoms had been present
during less than 6 months had a mean total symptom score
Table 1 Baseline data of 342 patients with functional dyspepsia
treated with levosulpiride
Data Patients
n (%)
Men/women 151/191
Age, years, mean (SD) 38.8 (12.3)
Duration of symptoms, months, mean (SD) 10.2 (10.7)
<6 months, n (%) 148 (43.3)
6–12 months 76 (22.2)
>12 months 118 (34.5)
Alcohol (mean 22.5g ethanol/day), n (%) 77 (22.5)
Current smokers, n (%) 25 (7.3)
Concomitant medication
Prokinetic drugs 88 (25.7)
Proton pump inhibitors 47 (13.6)
Antidopaminergic prokinetic agents 41 (11.8)
Anti-H2 agents 21 (6.1)
Antacids 30 (8.7)
Antispasmolytic drugs 20 (5.8)
Digestive enzymes 4 (1.2)
Abbreviations: SD, standard deviation.Therapeutics and Clinical Risk Management 2007:3(1) 152
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of 6.2 compared with 6.7 in patients with longer evolution
of functional dyspepsia. On the other hand, although patients
were not randomly selected for the two dosing scheduled
arms, there was a trend to prescribe the daily dose of
levosulpiride of 50 mg twice (BID) daily in patients with
shorter duration of symptoms and the daily dose of 75 mg
TID in patients with longer duration of symptoms.
Endoscopic abnormalities were recorded in 23.4% of
patients. However, as expected, the number of patients with
endoscopic abnormalities was significantly higher among
patients with nonerosive reflux disease than in those with
dysmotility-like dyspepsia (33.3% vs 13.3%, p<0.01).
Alcohol consumption was recorded in 22.5% of patients
(mean 22.2 [8.7 g] ethanol per day) and current smoking in
7.3%. Other underlying conditions, such as diabetes,
hypertension, previous surgery unrelated to the current
diagnosis, were found in less than 1% of patients. With
regard to history of alcohol consumption and cigarette
smoking, there were no significant differences according
to diagnoses of dysmotility-like dyspepsia or nonerosive
reflux disease, but a significantly higher percentage of
patients with duration of dyspeptic symptoms >6 or 12
months reported alcohol consumption (34.8%) and smoking
(8.2%) compared with patients with duration of dyspeptic
symptoms <6 months (8.4% and 1.4%, respectively) (p<
0.05). The mean systolic blood pressure was 119.7
(12.2) mm Hg, diastolic blood pressure 74.7 (8.1) mm Hg,
and heart rate 77.6 (7.1) beats/min.
Effectiveness
At the 15-day visit, a decrease greater than 50% in the total
symptom score was observed. The total symptom score
decreased significantly (p< 0.001) from a mean (SD) of 6.5
(2.5) at baseline to 3.1 (2.0) at visit 1, 1.4 (1.6) at visit 2,
and 1.2 (1.7) at visit 3 (Figure 1). The frequency and
intensity of individual symptoms showed a statistically
significant decrease (p<0.001) at all visits compared with
baseline. At the 30-day visit, all symptoms had almost
disappeared, a trend that was maintained until the last visit
(Table 2). Statistically significant differences regarding the
reduction of individual symptoms and total symptom score
between the groups of patients with dysmotility-like
dyspepsia and nonerosive reflux disease were not found.
The percentages of patients rating nausea, pyrosis,
regurgitation, and postprandial upper abdominal fullness as
Table 2 Comparison of individual symptoms at baseline and at the end of the study in 342 patients with functional dyspepsia
treated with levosulpiride.
Symptoms Intensity of symptoms Frequency of symptoms
Absent Mild Moderate Severe Absent 1–2 days 3–4 days ≥ ≥ ≥ ≥ ≥5 days Daily
Abdominal distention
Baseline 46 (13.5) 54 (15.8) 202 (59.1) 38 (11.1) 46 (13.6) 54 (15.9) 60 (17.7) 82 (24.2) 97 (28.6)
Visit 3 (60 days) 213 (66.4) 93 (29.0) 14 (4.4) 1 (0.3) 213 (66.4) 52 (16.2) 22 (6.9) 10 (3.1) 24 (7.5)
Upper abdominal pain/
discomfort
Baseline 57 (16.8) 126 (37.1) 131 (38.5) 26 (7.6) 57 (16.8) 59 (17.4) 74 (21.8) 62 (18.2) 88 (25.9)
Visit 3 (60 days) 228 (71.0) 88 (27.4) 4 (1.2) 1 (0.3) 228 (71.0) 33 (10.3) 13 (4.0) 10 (3.1) 37 (11.5)
Postprandial fullness
Baseline 51 (14.9) 71 (20.8) 185 (54.1) 33 (9.6) 51 (15.0) 41 (12.1) 76 (22.4) 78 (22.9) 94 (27.6)
Visit 3 (60 days) 240 (74.8) 77 (24.0) 4 (1.2) 0 240 (74.8) 45 (14.0) 22 (6.9) 4 (1.2) 10 (3.1)
Early satiety
Baseline 104 (30.7) 129 (38.1) 78 (23.0) 28 (8.3) 104 (30.8) 44 (13.0) 84 (24.9) 41 (12.1) 65 (19.2)
Visit 3 (60 days) 283 (88.7) 33 (10.3) 2 (0.6) 1 (0.3) 283 (89.0) 22 (6.9) 6 (1.9) 3 (0.9) 4 (1.3)
Nausea (related with
food ingestion)
Baseline 182 (53.5) 95 (27.9) 43 (12.6) 20 (5.9) 182 (53.5) 64 (18.8) 36 (10.6) 20 (5.9) 38 (11.2)
Visit 3 (60 days) 310 (96.9) 10 (3.1) 0 0 310 (96.9) 8 (1.5) 0 0 2 (0.6)
Pyrosis
Baseline 218 (63.9) 67 (19.6) 50 (14.7) 6 (1.8) 218 (63.9) 43 (12.6) 38 (11.1) 13 (3.8) 29 (8.5)
Visit 3 (60 days) 296 (92.2) 24 (7.5) 0 1 (0.3) 296 (92.2) 13 (4.0) 1 (0.3) 2 (0.6) 9 (2.8)
Regurgitation
Baseline 283 (83.0) 34 (10.0) 21 (6.2) 3 (0.9) 283 (83.0) 26 (7.6) 12 (3.5) 2 (0.6) 18 (5.3)
Visit 3 (60 days) 313 (97.5) 8 (2.5) 0 0 313 (97.5) 2 (0.6) 1 (0.3) 0 5 (1.6)
Note: p=0.001 for the comparisons of intensity and frequency of symptoms between baseline and visit 3.Therapeutics and Clinical Risk Management 2007:3(1) 153
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severe or moderate had decreased to practically 0% at the
end of the study (Figures 2 to 5).
Concomitant medication in all visits and diagnostic
groups was lower than 1%. Compliance with treatment was
higher than 96% in all cases (98.8% at the 15-day visit and
96.9% at the final visit). The effectiveness of treatment was
considered excellent or good by 92.5% of physicians and
90.3% of patients at the 30-day visit, and by 93.4% of
physicians and 91% of patients at the 60-day visit.
In the multivariate analysis, response to treatment with
levosulpiride was 4.13 higher in smokers compared with
non-smokers, 0.53 greater in patients with nonerosive reflux
disease compared with patients with dysmotility-like
dyspepsia, and 0.17 times higher in patients with both
diagnoses compared with patients with a single diagnosis.
Doses of levosulpiride were not selected as predictors of
response.
Safety
Treatment with levosulpiride was well tolerated and only
40 adverse events were recorded (galactorrhea 26.7%,
somnolence 17.8%, fatigue 11.1%, headache 11.5) and no
patient had to abandon the study due to side effects. Most
side effects were considered possibly or probably related to
the study medication as the events recorded were those
reported in the product’s technical form. A total of 66.7%
Figure 1 Decrease of total symptom score during the study.
Figure 2 Changes in the severity of nausea throughout the study.
Figure 3 Changes in the severity of pyrosis throughout the study.
Figure 4 Changes in the severity of regurgitation throughout the study.
Figure 5 Changes in the severity of abdominal fullness throughout the study.Therapeutics and Clinical Risk Management 2007:3(1) 154
Lozano et al
of side effects occurred during the first 15 days of treatment
with levosulpiride. As shown in Figure 6, the intensity of
adverse events was higher at the first visit and the few
adverse events still present at follow-up were of mild
intensity.
Discussion
This descriptive, observational, multinational study in which
levosulpiride was administered to patients with functional
dyspepsia according to indications of use in daily practice
confirms the effectiveness and safety of this prokinetic agent,
which is in accordance with previous data reported in the
literature. On the other hand, trials in functional dyspepsia
report placebo response rates of 30% to 40% (Talley et al
2006). This study has several important limitations. The
principal limitations were the open-label design and the
absence of a comparison group. Another limitation was that
the study was based on criteria of Rome II consensus report
(Talley et al 1999). The Rome III committee recommends
the term “dyspepsia” be restricted to patients with epigastric
pain or burning, postprandial fullness, or early satiation
(Tack et al 2006). The committee further opined that the
term “functional dyspepsia” has limited utility and, based
on factor analysis data, suggested that there are specific
syndromes (epigastric pain syndromes and postprandial
distress syndrome) that can be identified and may better
characterize those patients formally labeled as having
functional dyspepsia. This new classification remains to be
prospectively tested, and, at this stage, abandonment of the
term “functional dyspepsia” seems premature.
Although these limitations should be taken into account
when interpreting the results of this study, the present
findings, however, add evidence of the efficacy of
levosulpiride in different geographical settings mostly Latin
American countries, showing that differences in lifestyle
and behavioral and environmental factors had no influence
on the distinct pathophysiological abnormalities present in
subgroups of patients with this heterogeneous disorder.
Levosulpiride has demonstrated an excellent effectiveness
for the control of symptoms of both functional dyspepsia
and nonerosive reflux disease as shown by significant
decreases in the total symptom score and in the percentage
of individual clinical symptoms, including symptoms that
are less characteristic of the disease.
Levosulpiride was well tolerated and all side effects were
in accordance with those reported in previous studies and
coincided with the descriptions in the package insert of the
drug. The prokinetic agent cisapride has been a well-
evaluated form of pharmacological treatment for patients
with functional dyspepsia, but serious cardiovascular effects
with the use of this drug have been reported, which caused
removal of the drug from the US market in 2000. A recent
systematic review of management strategies (combinations
of initial investigation and empirical treatments) for
dyspeptic patients (Delaney et al 2005) concludes that PPIs
are effective in the treatment of dyspepsia in those trials
which may not adequately exclude patients with
gastroesophageal reflux disease. The relative efficacy of
histamine H2-receptor antagonists (H2RAs) and PPIs is
uncertain. Early investigation by endoscopy or H. pylori
testing may benefit some patients with dyspepsia but is not
cost effective as part of an overall management strategy.
The prokinetic effect of levosulpiride is mediated through
the blockade of enteric (neuronal and muscular) inhibitory
D2 receptors, and the ability to interact with 5-HT4 receptors.
The serotonergic (5-HT4) component of antidopaminergic
prokinetics enhances their therapeutic efficacy in
gastrointestinal disorders, such as functional dyspepsia and
diabetic gastroparesis (Mansi et al 1995; Tonini et al 2004).
The antagonism of central D2 receptors may lead to both
therapeutic (eg, antiemetic effect due to D2 receptor blockade
in the area postrema) and adverse (including
hyperprolactinemia and extrapyramidal dystonic reactions)
effects. Hyperprolactinemia is a side effect occurring with
all antidopaminergic prokinetics. In a randomized, double-
masked trial (Mearin et al 2004) in which the effects of the
effects of 8 weeks of treatment with either levosulpiride
25 mg TID (n=69) or cisapride 10 mg TID (n=71) were
compared. Both levosulpiride and cisapride improved
dyspeptic symptoms and decreased total symptom score
(79.9% and 71.3%, respectively); no significant statistical
Figure 6 Intensity of adverse events at the follow-up visits.Therapeutics and Clinical Risk Management 2007:3(1) 155
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difference between treatments was found (p=0.07 for total
symptom score). However, significantly more (p=0.03)
patients treated with cisapride had to abandon the trial
because of side effects.
The present data obtained in a large group of adult
patients with functional dyspepsia diagnosed and treated
by their physicians in daily practice confirm the effectiveness
and safety of a 4-week treatment regimen with levosulpiride
for the relief of dyspeptic symptoms. Further studies are
needed to examine our findings of better responses in
smokers compared with nonsmokers as well as in patients
with nonerosive reflux disease compared with dysmotility-
like functional dyspepsia.
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